US6232320B1
(en)
|
1998-06-04 |
2001-05-15 |
Abbott Laboratories |
Cell adhesion-inhibiting antiinflammatory compounds
|
CA2320730A1
(en)
*
|
1998-12-23 |
2000-07-06 |
Renhua Li |
Thrombin or factor xa inhibitors
|
PL350651A1
(en)
|
1999-03-09 |
2003-01-27 |
Upjohn Co |
4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents
|
WO2000075145A1
(en)
*
|
1999-06-03 |
2000-12-14 |
Abbott Laboratories |
Cell adhesion-inhibiting antiinflammatory compounds
|
NZ516348A
(en)
*
|
1999-06-23 |
2003-06-30 |
Aventis Pharma Gmbh |
Substituted benzimidazole
|
US6689883B1
(en)
|
1999-09-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Substituted pyridines and pyridazines with angiogenesis inhibiting activity
|
IL150525A0
(en)
*
|
2000-02-09 |
2003-02-12 |
Procter & Gamble |
2-carboxamide-benzimidazoles useful in the treatment and prevention of isochemic reperfusion injury
|
US7977333B2
(en)
|
2000-04-20 |
2011-07-12 |
Bayer Healthcare Llc |
Substituted pyridines and pyridazines with angiogenesis inhibiting activity
|
WO2003011219A2
(en)
|
2001-07-27 |
2003-02-13 |
Curis, Inc. |
Mediators of hedgehog signaling pathways, compositions and uses related thereto
|
JP2005502685A
(ja)
|
2001-08-30 |
2005-01-27 |
ファルマシア・アンド・アップジョン・カンパニー |
抗ウイルス剤としての4−チオキソ−4,7−ジヒドロ−チエノ[2,3−b]ピリジン−5−カルボキシアミド
|
WO2003020728A1
(en)
|
2001-08-30 |
2003-03-13 |
Pharmacia & Upjohn Company |
4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
|
AR038117A1
(es)
|
2002-01-14 |
2004-12-29 |
Upjohn Co |
Agentes antivirales derivados de la 4- oxo-4,7 -dihidrofuro [2,3-b]piridin-5-carboxamida
|
AR038118A1
(es)
|
2002-01-14 |
2004-12-29 |
Upjohn Co |
Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
|
AR038294A1
(es)
|
2002-01-14 |
2005-01-12 |
Upjohn Co |
Oxotieno(3,2-b)piridincarboxamidas como agentes antivirales
|
CA2485429A1
(en)
*
|
2002-05-06 |
2004-07-15 |
Vertex Pharmaceuticals Incorporated |
Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase
|
ATE323702T1
(de)
|
2002-08-06 |
2006-05-15 |
Astrazeneca Ab |
Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
|
US20060074102A1
(en)
*
|
2004-05-14 |
2006-04-06 |
Kevin Cusack |
Kinase inhibitors as therapeutic agents
|
RU2007101509A
(ru)
|
2004-06-17 |
2008-07-27 |
Уайт (Us) |
Способ получения антагонистов рецепторов гормона, высвобождающего гонадотропин
|
US7696210B2
(en)
|
2004-06-17 |
2010-04-13 |
Wyeth |
Gonadotropin releasing hormone receptor antagonists
|
MX2007001216A
(es)
|
2004-07-30 |
2007-03-23 |
Methylgene Inc |
Inhibidores de la senalizacion del receptor del factor de crecimiento endotelial vascular y del receptor del factor de crecimiento del hepatocito.
|
CA2575808A1
(en)
|
2004-08-02 |
2006-02-16 |
Osi Pharmaceuticals, Inc. |
Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
|
GB0420722D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
US7674822B2
(en)
|
2004-11-24 |
2010-03-09 |
Wyeth |
PTP1b inhibitors
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
US7534796B2
(en)
|
2005-02-18 |
2009-05-19 |
Wyeth |
Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7538113B2
(en)
|
2005-02-18 |
2009-05-26 |
Wyeth |
4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7582634B2
(en)
|
2005-02-18 |
2009-09-01 |
Wyeth |
7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7531542B2
(en)
|
2005-05-18 |
2009-05-12 |
Wyeth |
Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
|
KR101378716B1
(ko)
|
2005-05-20 |
2014-04-10 |
메틸진 인코포레이티드 |
Vegf 수용체 및 hgf 수용체 신호전달의 억제제
|
NZ563774A
(en)
|
2005-05-20 |
2010-04-30 |
Methylgene Inc |
Inhibitors of VEGF receptor and HGF receptor signaling
|
US7582636B2
(en)
|
2005-05-26 |
2009-09-01 |
Wyeth |
Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
|
JP5071374B2
(ja)
|
2005-07-14 |
2012-11-14 |
アステラス製薬株式会社 |
ヘテロ環ヤヌスキナーゼ3阻害剤
|
EP2251341A1
(en)
|
2005-07-14 |
2010-11-17 |
Astellas Pharma Inc. |
Heterocyclic Janus kinase 3 inhibitors
|
EP1917251B1
(de)
|
2005-08-21 |
2013-04-03 |
Abbott GmbH & Co. KG |
5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
|
EP2270014A1
(en)
|
2005-09-22 |
2011-01-05 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
MY159449A
(en)
|
2005-12-13 |
2017-01-13 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
AR059898A1
(es)
|
2006-03-15 |
2008-05-07 |
Janssen Pharmaceutica Nv |
Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
|
EP2043655A2
(en)
|
2006-04-25 |
2009-04-08 |
Astex Therapeutics Limited |
Purine and deazapurine derivatives as pharmaceutical compounds
|
US8227603B2
(en)
|
2006-08-01 |
2012-07-24 |
Cytokinetics, Inc. |
Modulating skeletal muscle
|
RS54542B1
(en)
|
2006-08-02 |
2016-06-30 |
Cytokinetics, Inc. |
CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INCLUDING IMIDAZOPYRIMIDINE
|
US8299248B2
(en)
|
2006-08-02 |
2012-10-30 |
Cytokinetics, Incorporated |
Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
|
CA2673038C
(en)
|
2006-12-22 |
2015-12-15 |
Incyte Corporation |
Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
|
TW200845978A
(en)
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
US7851484B2
(en)
|
2007-03-30 |
2010-12-14 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
TR201903488T4
(tr)
|
2007-06-13 |
2019-04-22 |
Incyte Holdings Corp |
Janus kinaz inhibitörü (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-siklopentilpropannitril tuzlarının kullanımı.
|
NZ584152A
(en)
|
2007-09-14 |
2011-11-25 |
Ortho Mcneil Janssen Pharm |
1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
|
PT2203439E
(pt)
|
2007-09-14 |
2011-02-11 |
Ortho Mcneil Janssen Pharm |
4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas
|
PL2201012T3
(pl)
|
2007-10-11 |
2014-11-28 |
Astrazeneca Ab |
Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
|
CN101910152B
(zh)
|
2007-11-16 |
2014-08-06 |
因塞特公司 |
作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺
|
AR070479A1
(es)
|
2008-02-26 |
2010-04-07 |
Takeda Pharmaceutical |
Derivado heterociclico fusionado y su uso
|
WO2009109035A1
(en)
|
2008-03-05 |
2009-09-11 |
Methylgene Inc. |
Inhibitors of protein tyrosine kinase activity
|
UA101493C2
(ru)
|
2008-03-11 |
2013-04-10 |
Инсайт Корпорейшн |
Производные азетидина и циклобутана как ингибиторы jak
|
WO2009132202A2
(en)
|
2008-04-24 |
2009-10-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
BRPI0918055A2
(pt)
|
2008-09-02 |
2015-12-01 |
Addex Pharmaceuticals Sa |
derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
|
JP5690277B2
(ja)
|
2008-11-28 |
2015-03-25 |
ジャンセン ファーマシューティカルズ, インコーポレイテッド. |
代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
|
US8765727B2
(en)
|
2009-01-23 |
2014-07-01 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
NZ596078A
(en)
|
2009-05-12 |
2013-06-28 |
Janssen Pharmaceuticals Inc |
1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
|
CN102439015B
(zh)
|
2009-05-12 |
2015-05-13 |
杨森制药有限公司 |
1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
|
WO2010135650A1
(en)
|
2009-05-22 |
2010-11-25 |
Incyte Corporation |
N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
|
AR076920A1
(es)
|
2009-05-22 |
2011-07-20 |
Incyte Corp |
3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)octano-o heptano--nitrilo como inhibidores de jak
|
US9096518B2
(en)
|
2009-06-22 |
2015-08-04 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
WO2010151317A1
(en)
|
2009-06-22 |
2010-12-29 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
WO2011044481A1
(en)
|
2009-10-09 |
2011-04-14 |
Incyte Corporation |
Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
PT3050882T
(pt)
|
2010-03-10 |
2018-04-16 |
Incyte Holdings Corp |
Derivados de piperidin-4-ilazetidina como inibidores de jak1
|
EP2574168B9
(en)
|
2010-05-21 |
2016-10-05 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
CN102260270A
(zh)
*
|
2010-05-28 |
2011-11-30 |
中国科学院上海药物研究所 |
N-(2-甲基呋喃[2,3-d]嘧啶-4-基)丙烯酰胺、其制备方法及其用途
|
CA2814998C
(en)
|
2010-11-08 |
2019-10-29 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
US9271967B2
(en)
|
2010-11-08 |
2016-03-01 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
|
US8993591B2
(en)
|
2010-11-08 |
2015-03-31 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
|
CA2818545C
(en)
|
2010-11-19 |
2019-04-16 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
AU2011329734B2
(en)
|
2010-11-19 |
2015-05-28 |
Incyte Holdings Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
WO2012088015A2
(en)
|
2010-12-22 |
2012-06-28 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
PT2675451E
(pt)
|
2011-02-18 |
2015-10-16 |
Incyte Corp |
Terapia de combinação com inibidores mtor/jak
|
ES2761311T3
(es)
|
2011-04-01 |
2020-05-19 |
Astrazeneca Ab |
Tratamiento terapéutico
|
ES2560611T3
(es)
|
2011-06-20 |
2016-02-22 |
Incyte Holdings Corporation |
Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
|
CA2841111A1
(en)
|
2011-07-08 |
2013-01-17 |
Novartis Ag |
Novel pyrrolo pyrimidine derivatives
|
CA2849213A1
(en)
|
2011-07-13 |
2013-01-17 |
Cytokinetics, Inc. |
Combination of riluzole and ck-2017357 for treating als
|
CA2844507A1
(en)
|
2011-08-10 |
2013-02-14 |
Novartis Pharma Ag |
Jak pi3k/mtor combination therapy
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
MY175800A
(en)
|
2011-11-30 |
2020-07-09 |
Astrazeneca Ab |
Combination treatment of cancer
|
WO2013102145A1
(en)
|
2011-12-28 |
2013-07-04 |
Global Blood Therapeutics, Inc. |
Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
|
CN104135859B
(zh)
|
2011-12-28 |
2017-06-27 |
全球血液疗法公司 |
取代的苯甲醛化合物及其用于增加组织氧合的方法
|
AU2013204533B2
(en)
|
2012-04-17 |
2017-02-02 |
Astrazeneca Ab |
Crystalline forms
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
BR112015010663B1
(pt)
|
2012-11-15 |
2022-12-06 |
Incyte Holdings Corporation |
Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
|
UA121532C2
(uk)
|
2013-03-06 |
2020-06-10 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки при отриманні інгібітора jak
|
US10100043B2
(en)
|
2013-03-15 |
2018-10-16 |
Global Blood Therapeutics, Inc. |
Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
|
US9458139B2
(en)
|
2013-03-15 |
2016-10-04 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
US8952171B2
(en)
|
2013-03-15 |
2015-02-10 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
JP6426694B2
(ja)
|
2013-03-15 |
2018-11-21 |
グローバル ブラッド セラピューティクス インコーポレイテッド |
ヘモグロビンの修飾のための化合物及びその使用
|
US9422279B2
(en)
|
2013-03-15 |
2016-08-23 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
US20140274961A1
(en)
|
2013-03-15 |
2014-09-18 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
JP6463327B2
(ja)
|
2013-03-15 |
2019-01-30 |
グローバル ブラッド セラピューティクス インコーポレイテッド |
ヘモグロビンの修飾のための化合物及びその使用
|
SG11201507453VA
(en)
|
2013-03-15 |
2015-10-29 |
Global Blood Therapeutics Inc |
Compounds and uses thereof for the modulation of hemoglobin
|
US10266551B2
(en)
|
2013-03-15 |
2019-04-23 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
US9604999B2
(en)
|
2013-03-15 |
2017-03-28 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
JO3368B1
(ar)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
|
EP3721873A1
(en)
|
2013-08-07 |
2020-10-14 |
Incyte Corporation |
Sustained release dosage forms for a jak1 inhibitor
|
JO3367B1
(ar)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
|
EA201992707A1
(ru)
|
2013-11-18 |
2020-06-30 |
Глобал Блад Терапьютикс, Инк. |
Соединения и их применения для модуляции гемоглобина
|
CA2929858C
(en)
|
2013-11-22 |
2022-03-29 |
CL BioSciences LLC |
Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
|
SI3096790T1
(sl)
|
2014-01-21 |
2019-11-29 |
Janssen Pharmaceutica Nv |
Kombinacije, ki vsebujejo pozitivne aleostrične modulatorje ali ortosterične agoniste metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba
|
ME03518B
(me)
|
2014-01-21 |
2020-04-20 |
Janssen Pharmaceutica Nv |
Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
|
DK3102208T4
(da)
|
2014-02-07 |
2024-08-26 |
Global Blood Therapeutics Inc |
Krystallinsk polymorph af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
MA41841A
(fr)
|
2015-03-30 |
2018-02-06 |
Global Blood Therapeutics Inc |
Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
|
EP3383392A1
(en)
|
2015-12-04 |
2018-10-10 |
Global Blood Therapeutics, Inc. |
Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
|
TWI752307B
(zh)
|
2016-05-12 |
2022-01-11 |
美商全球血液治療公司 |
新穎化合物及製造化合物之方法
|
CN107513067A
(zh)
|
2016-06-16 |
2017-12-26 |
北京赛林泰医药技术有限公司 |
含有取代环戊基的吡咯并嘧啶化合物
|
US10154992B2
(en)
*
|
2016-07-12 |
2018-12-18 |
The Regents Of The University Of California |
Compounds and methods for treating HIV infection
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
TWI778983B
(zh)
|
2016-10-12 |
2022-10-01 |
美商全球血液治療公司 |
包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
EA202091830A1
(ru)
|
2018-01-30 |
2020-12-29 |
Инсайт Корпорейшн |
Способы и промежуточные соединения для получения ингибитора jak
|
PL3759109T3
(pl)
|
2018-02-26 |
2024-03-04 |
Gilead Sciences, Inc. |
Podstawione związki pirolizyny jako inhibitory replikacji hbv
|
MA52219A
(fr)
|
2018-03-30 |
2021-02-17 |
Incyte Corp |
Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
|
EP3860975B1
(en)
|
2018-10-01 |
2023-10-18 |
Global Blood Therapeutics, Inc. |
Modulators of hemoglobin for the treatment of sickle cell disease
|
US11168093B2
(en)
|
2018-12-21 |
2021-11-09 |
Celgene Corporation |
Thienopyridine inhibitors of RIPK2
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|